These survive one way or another. There are no time lines as others are driving it. They drove GBM agile but didn't communicate to the market what the target was as they didn't know and probably didn't ask. they had the data to know it wasn't the holy grail. based on what's been released by others it will get FDA approval as long as another all encompassing drug isn't put forward by others.
